Alabama is currently home to 1235 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
HCRN Core Data Project: Characterizing Patient Populations in the Hydrocephalus Clinical Research Network (HCRN)
NCT00670735
Recruiting
The Hydrocephalus Clinical Research Network (HCRN) has been established by philanthropic funding to conduct multi-institutional research (clinical trials and observational studies) on pediatric hydrocephalus. In addition to philanthropic funding, the HCRN has also received an NIH NINDS Challenge Grant to support the network infrastructure which allows for the conduct of this and other network studies. The HCRN consists of multiple Clinical Centers and the Data Coordinating Center (DCC). The HCRN... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
12/13/2024
Locations: Children's Hospital of Alabama, University of Alabama, Birmingham, Alabama
Conditions: Pediatric Hydrocephalus
Register for Updates
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML
NCT06679582
Recruiting
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children. To be treated in this trial children must have a leukemia which did not respond or recurred after prior treatment. Luveltamab tazevibulin is an antibody-drug conjugate, which brings tazevibulin, an anticancer drug, to a molecule called FOLR1, present on the surface of CBFA2T3::GLIS2 AML... Read More
Gender:
ALL
Ages:
Between 1 day and 12 years
Trial Updated:
12/12/2024
Locations: Childrens Hospital of Alabama, Birmingham, Alabama
Conditions: Acute Myeloid Leukemia (AML)
Register for Updates
A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
NCT06423703
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/12/2024
Locations: ALLEVIATE 2 Site 001108, Sheffield, Alabama
Conditions: Acute Pain
Register for Updates
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
NCT05805709
Recruiting
The COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal intervention to usual care on hospital-free days through 90 days of study follow up. The primary study hypothesis is that patients randomized to the intervention will have increased odds of more hospital-free days through 90 days (primary clinical) compared to those randomized to usual care. Key secondary hypotheses will investigate the impact of the intervention on rates of major adverse kidney events, rate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Acute Kidney Injury
Register for Updates
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
NCT05643534
Recruiting
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and \<18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/12/2024
Locations: G & L Research, LLC, Foley, Alabama
Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Register for Updates
Infant-Maternal Partnership and Cognitive Training Study for Preterm Infants
NCT06335524
Recruiting
This study will test the hypothesis that in preterm infants a caregiver-implemented early developmental intervention (EDI) using finger puppets to develop joint attention and encourage interactive communication with routine EDI care including Bookworm training compared with routine EDI care including Bookworm training alone will increase the Ages and Stages Questionnaire® score at 12 months corrected age.
Gender:
ALL
Ages:
Between 1 week and 17 weeks
Trial Updated:
12/11/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Child Development, Infant Development, Infant, Premature, Diseases
Register for Updates
RESTORE: An RCT to Evaluate the Efficacy of the Revi System
NCT06217328
Recruiting
The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/11/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Urinary Urge Incontinence
Register for Updates
The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies
NCT06006546
Recruiting
This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/11/2024
Locations: Birmingham, Birmingham, Alabama
Conditions: Chronic HIV Infection
Register for Updates
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
NCT05971251
Recruiting
Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Cancer and Aging Resilience Evaluation in Older Adults with Hematologic Malignancies: the CARE-Heme Registry
NCT05556928
Recruiting
The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information that would lend support for future research in this vulnerable population.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
12/11/2024
Locations: Kirklin Clinic of UAB Hospital, Birmingham, Alabama
Conditions: Multiple Myeloma, Amyloidosis, Plasma Cell Leukemia
Register for Updates
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT05388708
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Children's of Alabama, Birmingham, Alabama
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Register for Updates
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
NCT05183048
Recruiting
This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately determine size and location of primary tumors compared to standard of care Fludeoxyglucose (18F-FDG) -PET/MRI in newly diagnosed patients with head and neck squamous cell carcinoma (HNSCC) who are undergoing surgical resection. This study is for imaging purposes only and is not a treatment study. The results of this study wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: UAB, Birmingham, Alabama
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates